Lucid Diagnostics grants 620,000 RS to its COO

Lucid Diagnostics Inc. reported that President and COO Shaun O'Neil acquired 620,000 shares of common stock through a restricted stock grant under the company’s 2018 Equity Plan.

Rhea-AI Filing Summary

Lucid Diagnostics Inc. reported that President and COO Shaun O'Neil acquired 620,000 shares of common stock through a restricted stock grant under the company’s 2018 Equity Plan. The restricted stock has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed. Following this award, O'Neil directly holds 1,446,763 shares of common stock.

Insider Trade Summary

Grant/Award: 620,000 shares

Grant/Award 1 txn

Insider O'Neil Shaun

Role President and COO

Type	Security	Shares	Price	Value
Grant/Award	Common stock	620,000	$0.00	$0.00

Holdings After Transaction: Common stock — 1,446,763 shares (Direct)

Footnotes (1)

1. F1. Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Lucid Diagnostics (LUCD) report for Shaun O'Neil?

Lucid Diagnostics reported a restricted stock grant to President and COO Shaun O'Neil. He was awarded 620,000 shares of common stock under the 2018 Equity Plan, classified as a grant, award, or other acquisition rather than an open-market purchase or sale.

How many Lucid Diagnostics (LUCD) shares did Shaun O'Neil receive in this Form 4?

Shaun O'Neil received 620,000 shares of Lucid Diagnostics common stock. These shares were granted as restricted stock at a reported price of $0.00 per share, reflecting an equity compensation award rather than a cash transaction in the open market.

When do Shaun O'Neil’s new Lucid Diagnostics (LUCD) restricted shares vest?

The restricted stock granted to Shaun O'Neil vests on May 20, 2029. The award has a single vesting date and is subject to forfeiture if he does not complete the requisite service period specified under Lucid Diagnostics’ 2018 Equity Plan.

What is Shaun O'Neil’s total Lucid Diagnostics (LUCD) share ownership after this grant?

After the restricted stock grant, Shaun O'Neil directly owns 1,446,763 shares. This total reflects his holdings of Lucid Diagnostics common stock following the acquisition of 620,000 restricted shares, as reported in the Form 4 filing.

Is the Lucid Diagnostics (LUCD) Form 4 transaction a market purchase or sale?

The transaction is a grant, award, or other acquisition, not a market trade. The Form 4 classifies the code as “A,” indicating an equity award of restricted stock rather than an open-market buy or sell transaction in Lucid Diagnostics shares.

What conditions apply to Shaun O'Neil’s Lucid Diagnostics (LUCD) restricted stock grant?

The restricted stock is subject to service-based vesting and possible forfeiture. All 620,000 shares vest on May 20, 2029, but may be forfeited if O'Neil does not complete the required service period under the company’s 2018 Equity Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/24/2026 - 06:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Neil Shaun

(Last) (First) (Middle)

360 MADISON AVENUE, 25TH FLOOR

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lucid Diagnostics Inc. [ LUCD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	02/20/2026		A		620,000(1)	A	$0	1,446,763	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed.

	/s/ Michael A. Gordon, by power of attorney	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.